In 2018, burosumab, an antibody that inhibits FGF23 activity directly, became the first and only US Food and Drug Administration–approved treatment to date for XLH, with approval extended to patients 6 months of age and older in 2019 [6, 7, 20, 21]. Here, FGF23 is linked to X-linked dominant hypophosphatemic rickets.